# MOTS-c benefits: what the research actually shows, graded by evidence

**By TelosRX Editorial Team** · 2026-10-29

**MOTS-c benefits are studied mainly in mice and cells, where the peptide improved insulin sensitivity, exercise capacity and age-related physical decline. In people, the evidence so far only shows that the body's own MOTS-c levels shift with age, exercise and diabetes. No controlled human trial of injected MOTS-c has been published, and MOTS-c is not FDA-approved.**

Search for MOTS-c benefits and you will find long lists: fat loss, endurance, longevity, better blood sugar. Some trace back to real studies. Others stretch a mouse result into a human promise.

This guide does something simpler. It takes each claimed benefit and grades it by the strongest evidence behind it: human, animal, cell or none. Then it gives a short, honest note on each. _Also searched as: mots-c peptide benefits, mots c benefits, benefits of mots-c, motsc and peptide mots-c._

![MOTS-c benefits research: close-up of a compounded MOTS-c peptide vial](https://telosrx.com/cdn/shop/t/39/assets/mots-c-vial-macro.png)

## What MOTS-c is, in one paragraph

MOTS-c is a 16-amino-acid peptide encoded inside your mitochondrial DNA, in the region that codes for 12S ribosomal RNA. It was first described in 2015 by a team at the University of Southern California, who showed it targets skeletal muscle and activates AMPK, the cell's energy sensor, through effects on the folate cycle ([Lee et al., 2015](https://pubmed.ncbi.nlm.nih.gov/25738459/)). It acts like a signal from the mitochondria to the rest of the body. For the fuller backstory, see our [MOTS-c metabolic research overview](https://www.telosrx.com/blogs/peptides/mots-c-mitochondrial-peptide-metabolic-research).

## How we graded each MOTS-c benefit

Each row in the scorecard below uses the highest level of evidence we could verify on PubMed:

-   **Human:** a controlled trial in people taking MOTS-c.
-   **Animal:** MOTS-c given to mice or rats, with a measured result.
-   **Cell:** results in cultured cells only.
-   **None:** no direct evidence, only theory or loose association.

Observational human data, such as blood levels in older adults, is noted in the table but does not count as "human" evidence for a treatment effect. That distinction matters more for MOTS-c benefits than for almost any other peptide.

## The MOTS-c benefits scorecard

| Claimed MOTS-c benefit | Strongest evidence found | Evidence grade |
| --- | --- | --- |
| **Insulin sensitivity and glucose handling** | Mice on high-fat diets and aged mice; human data are associations only (lower levels in type 2 diabetes, a gene variant linked to diabetes risk in men) | Animal |
| **Weight and body fat** | Diet-induced weight gain prevented in mice; in people, higher levels tracked with more liver fat, not less | Animal |
| **Exercise capacity** | Better running performance in young, middle-aged and old mice; exercise raises the body's own MOTS-c in people | Animal |
| **Age-related physical decline** | Late-life treatment in old mice improved physical capacity | Animal |
| **Muscle preservation** | Less muscle loss in immobilised mice | Animal |
| **Bone density** | Less bone loss in mice after ovary removal; reduced bone-resorbing cell formation in culture | Animal and cell |
| **Inflammation** | Lower inflammatory signals in mouse models of bone erosion and immobilisation | Animal |
| **Cellular stress response** | Moves to the nucleus and switches on antioxidant-response genes in stressed cells | Cell |
| **Human lifespan or anti-aging** | A gene variant in long-lived Japanese populations was proposed as a link; no treatment data | None |
| **Any benefit of injected MOTS-c in people** | No published controlled human trial of MOTS-c itself | None |

The pattern is clear. Not one of the MOTS-c peptide benefits reaches the "human" grade. That does not mean MOTS-c does nothing in people. It means nobody can yet say what it does, at what dose or for whom, which is why the [MOTS-c protocol at telos rx](https://www.telosrx.com/pages/mots-c) is always set by a provider.

Want a licensed provider to weigh this evidence against your own health history? Complete a short online intake. A US-licensed provider reviews it asynchronously, with no scheduled appointment.

[See if MOTS-c is right for you](https://www.telosrx.com/pages/mots-c)

## MOTS-c benefits, one by one

### Insulin sensitivity and glucose handling

This is the founding claim. In the 2015 study, MOTS-c treatment in mice prevented both age-dependent and high-fat-diet-induced insulin resistance ([Lee et al., 2015](https://pubmed.ncbi.nlm.nih.gov/25738459/)). A 2025 study found MOTS-c levels fall with aging in mouse pancreatic islet cells, and that treatment reduced islet cell senescence in mouse models. The same paper reported lower circulating MOTS-c in people with type 2 diabetes than in healthy controls ([Kong et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40855115/)).

There is also a genetic clue. An East Asian variant that changes one amino acid in MOTS-c (called K14Q) was linked to higher type 2 diabetes prevalence in men across more than 27,000 people, especially in less active men ([Zempo et al., 2021](https://pubmed.ncbi.nlm.nih.gov/33468709/)). Our [MOTS-c and insulin resistance guide](https://www.telosrx.com/blogs/peptides/mots-c-for-insulin-resistance-research) goes deeper. Grade: animal, with supportive human associations.

### Weight and body fat

Mice on a high-fat diet gained less weight with MOTS-c ([Lee et al., 2015](https://pubmed.ncbi.nlm.nih.gov/25738459/)). Human data run the other way at first glance: in 125 adults without diabetes, higher plasma MOTS-c tracked with more liver and abdominal fat ([Sequeira et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34419510/)). The authors suggest a stress response, not a cause. Weight-related benefits of MOTS-c in people are not established. Grade: animal.

### Exercise capacity

MOTS-c improved physical performance in young, middle-aged and old mice, and in people, exercise raised the body's own MOTS-c in muscle and blood ([Reynolds et al., 2021](https://pubmed.ncbi.nlm.nih.gov/33473109/)). A Swedish study saw only a trend toward higher plasma MOTS-c after endurance cycling ([von Walden et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34351816/)). This is why it gets called an "exercise mimetic," a label our [exercise mimetic explainer](https://www.telosrx.com/blogs/peptides/mots-c-exercise-mimetic-research-explained) unpacks. For tested athletes, [USADA](https://www.usada.org/spirit-of-sport/what-is-mots-c-peptide/) notes that MOTS-c is prohibited at all times under WADA category S4, hormone and metabolic modulators, as an AMPK activator. Grade: animal.

### Age-related physical decline

In the same 2021 study, intermittent MOTS-c started in very old mice (about 23.5 months) improved physical capacity and markers of healthspan ([Reynolds et al., 2021](https://pubmed.ncbi.nlm.nih.gov/33473109/)). Healthspan is not lifespan, and old mice are not old people. Our companion piece on [MOTS-c longevity and aging research](https://www.telosrx.com/blogs/peptides/mots-c-longevity-aging-research) covers this in detail. Grade: animal.

### Muscle preservation

In mice with a leg immobilised for eight days, daily MOTS-c injections reduced muscle loss and lowered several inflammatory markers ([Kumagai et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38170165/)). No human study has tested MOTS-c for muscle loss. Grade: animal.

### Bone density

In mice that had their ovaries removed, a model of post-menopausal bone loss, 12 weeks of MOTS-c reduced bone loss and slowed the formation of bone-resorbing cells ([Ming et al., 2016](https://pubmed.ncbi.nlm.nih.gov/27237975/)). Grade: animal and cell.

### Inflammation

MOTS-c reduced inflammation and bone erosion in a mouse model of particle-induced osteolysis, partly through the AMPK pathway ([Yan et al., 2019](https://pubmed.ncbi.nlm.nih.gov/31369811/)). Similar anti-inflammatory signals appear in the immobilisation study above. Grade: animal.

### Cellular stress response

Under metabolic stress, MOTS-c moves from the mitochondria into the nucleus and regulates genes with antioxidant response elements, interacting with the transcription factor NRF2 ([Kim et al., 2018](https://pubmed.ncbi.nlm.nih.gov/29983246/)). This is the mechanism behind many of the claims above, but it was shown in cells. Grade: cell.

### Longevity and anti-aging in humans

A 2015 letter proposed that a MOTS-c gene variant common in Northeast Asia might help explain exceptional longevity in Japan ([Fuku et al., 2015](https://pubmed.ncbi.nlm.nih.gov/26289118/)). The authors themselves framed it as a question. There is no evidence that taking MOTS-c extends human life. Grade: none.

Curious about the MOTS-c protocol? If a provider approves it, a licensed US pharmacy compounds MOTS-c as a subcutaneous injection, and your provider sets the dose and schedule.

[Learn about the MOTS-c protocol](https://www.telosrx.com/pages/mots-c)

## Why human evidence for MOTS-c benefits is so thin

Three reasons come up again and again:

1.  **It is new.** MOTS-c was only described in 2015. Most peptides take decades to move from mice to large human trials.
2.  **No published human trials.** We could not find a peer-reviewed controlled trial of MOTS-c itself in people on PubMed.
3.  **Observational data are easy to over-read.** Lower MOTS-c in older or diabetic people may be a marker, not a lever.

So read any list of the benefits of MOTS-c as "studied in mice for," not "does in people."

## Safety and the regulatory picture

MOTS-c is not FDA-approved for any use. Human safety data are very limited. Reported or theorised side effects include injection-site reactions, fatigue, headache, nausea and changes in blood sugar, which matters for anyone on diabetes medication. It is not for use in pregnancy or breastfeeding. Our upcoming [MOTS-c side effects guide](https://www.telosrx.com/blogs/peptides/mots-c-side-effects) covers this in more detail.

On regulation: in July 2026, the FDA's Pharmacy Compounding Advisory Committee voted to recommend adding MOTS-c to the list of bulk substances for compounding. FDA's briefing documents had recommended against. The vote is advisory and non-binding. On October 28, 2026, HHS announced an interim [enforcement discretion policy](https://www.federalregister.gov/d/2026-22192): it does not intend to take action against state-licensed pharmacies that compound single-ingredient MOTS-c for subcutaneous or intramuscular injection with a valid prescription, under strict sourcing, testing and reporting conditions. It is temporary while FDA rulemaking continues, it is not FDA approval, and HHS can revisit it. See our [PCAC vote explainer](https://www.telosrx.com/blogs/peptides/pcac-july-2026-peptide-vote-explained) and the [MOTS-c legal status guide](https://www.telosrx.com/blogs/peptides/is-mots-c-fda-approved-legal-status).

Grey-market vials labelled "research use only" have unverified identity, strength and sterility.

## How to explore MOTS-c benefits with a provider

At telos rx, the prescription route is online and asynchronous:

1.  **Online intake.** You answer questions about your health, medications and goals.
2.  **Provider review.** A US-licensed provider reviews your answers without a scheduled appointment. A prescription is required, subject to medical approval by a licensed provider, and approval is not guaranteed.
3.  **Licensed pharmacy.** If approved, a licensed US pharmacy compounds MOTS-c as a subcutaneous injection. Your provider sets the dose and schedule.
4.  **Ongoing care.** You can message the care team, and plans can be cancelled from the portal.

telos rx does not offer oral or tablet MOTS-c. You can read more on the [MOTS-c page](https://www.telosrx.com/pages/mots-c), or compare it with a related cellular-energy option in our [MOTS-c vs NAD+ comparison](https://www.telosrx.com/blogs/peptides/mots-c-vs-nad-plus).

## Frequently asked questions about MOTS-c benefits

### What are the main MOTS-c benefits studied so far?

The MOTS-c benefits studied most are better insulin sensitivity, resistance to diet-induced weight gain, improved exercise capacity and less age-related physical decline. Almost all of it comes from mouse and cell studies.

### Are MOTS-c benefits shown in humans?

No. Human evidence is limited to observational studies of the body's own MOTS-c levels, such as lower levels in older men and in people with type 2 diabetes. These studies show associations, not the effect of taking MOTS-c.

### What are the benefits of MOTS-c for weight loss?

In mice fed a high-fat diet, MOTS-c treatment prevented diet-induced weight gain. Weight loss benefits in humans are not established.

### Is mots c the same as MOTS-c?

Yes. mots c, motsc, mots-c peptide and peptide mots-c all refer to the same 16-amino-acid mitochondrial-derived peptide, first described in 2015.

### Is MOTS-c FDA-approved?

No. MOTS-c is not FDA-approved for any use. In July 2026 an FDA advisory committee voted to recommend adding it to the list of bulk substances for compounding, but that vote is non-binding. On October 28, 2026, HHS announced a temporary enforcement discretion policy for compounded single-ingredient MOTS-c under strict conditions while FDA rulemaking continues. That policy is not FDA approval.

### Can athletes use MOTS-c?

Tested athletes should not. According to USADA, MOTS-c is prohibited at all times under WADA category S4, hormone and metabolic modulators, as an AMPK activator. Check with your own federation too.

### How can I find out if MOTS-c is right for me?

At telos rx, you complete an online intake that a US-licensed provider reviews asynchronously. If appropriate, a licensed US pharmacy compounds MOTS-c as a subcutaneous injection. Every prescription is subject to medical approval by a licensed provider, and approval is not guaranteed.

You now know which MOTS-c benefits rest on mouse data and which rest on nothing yet. If you want a licensed provider to decide whether MOTS-c fits you, start a short online intake.

[Explore MOTS-c at telos rx](https://www.telosrx.com/pages/mots-c)

_This article is for general education and is not medical advice. MOTS-c is not FDA-approved for any use, and compounded MOTS-c has not been evaluated by the FDA for safety, effectiveness or quality. All prescriptions are subject to medical approval by a licensed provider; approval is not guaranteed. Individual experiences vary. telos rx is an online-first, asynchronous telehealth service, and medications are compounded by a licensed US pharmacy. MOTS-c is prohibited in sport under WADA category S4._

**Tags:** metabolic health, mitochondrial peptides, MOTS-c, MOTS-c benefits, peptide research

---

> Source: [Telos RX](https://www.telosrx.com/blogs/peptides/mots-c-benefits-research)
